Automated radiosynthesis of [ 18 F]CETO, a PET radiotracer for imaging adrenal glands, on Synthra RNplus
Journal of Labelled Compounds and Radiopharmaceuticals · 2024
DOI: 10.1002/jlcr.4078 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Labelled Compounds and Radiopharmaceuticals, 2024. Verfasst von Matthew Hird und 7 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Imaging Chemistry Laboratory, Wolfson Brain Imaging Centre, Department of Clinical Neuroscience, University of Cambridge, Cambridge, UK. Hauptthemen laut MEDLINE: Radiopharmaceuticals, Fluorine Radioisotopes. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council, National Institute for Health and Care Research.
Abstract (Originalsprache)
Primary aldosteronism (PA) is the leading secondary cause of hypertension. Determining whether one (unilateral) or both (bilateral) adrenal glands are the source of PA in a patient remains challenging, and yet it is a critical step in the decision whether to recommend potentially curative surgery (adrenalectomy) or lifelong medical therapy (typically requiring multiple drugs). Recently, we have developed a fluorine‐18 radiopharmaceutical [ 18 F]CETO to permit greater access to PA molecular imaging. Herein, we report an automated synthesis of this radiotracer. To manufacture the radiopharmaceutical routinely for clinical PET studies, we implemented an automated radiosynthesis method on a Synthra RNplus© synthesiser for which Cl‐tosyletomidate was used as the precursor for radiolabelling via nucleophilic [ 18 F]fluorination. [ 18 F]CETO was produced with 35 ± 1% ( n = 7), decay corrected and 25 ± 4% ( n = 7) non‐decay corrected radiochemical yield with molar activities ranging from 150 to 400 GBq/μmol. The GMP compliant manufacturing process produces a sterile formulated [ 18 F]CETO injectable solution for human use as demonstrated by the results of quality control. Automation of the radiosynthesis of [ 18 F]CETO should facilitate uptake by other adrenal centres and increase access to molecular imaging in PA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Imaging Chemistry Laboratory, Wolfson Brain Imaging Centre, Department of Clinical Neuroscience, University of Cambridge, Cambridge, UK.
- Radiopharmaceutical Unit, Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
- Uppsala Biomedicinska Centrum, BMC, Uppsala, Sweden.
- Welcome-MRC Institute of Metabolic Science and Department of Medicine, University of Cambridge, Cambridge Biomedical Campus, Cambridge, UK.
- Addenbrooke's Hospital, Cambridge Biomedical Campus, Cambridge, UK.
ORCID-Profile: Matthew Hird, Patrik Nordeman
Förderung
- Medical Research Council
- National Institute for Health and Care Research
Zitieren
APA
Hird, M., Russell, J. J., Corrigan, L. L., Boros, I., Nordeman, P., Antoni, G., Gurnell, M., & Aigbirhio, F. I. (2024). Automated radiosynthesis of [ 18 F]CETO, a PET radiotracer for imaging adrenal glands, on Synthra RNplus. Journal of Labelled Compounds and Radiopharmaceuticals. https://doi.org/10.1002/jlcr.4078
Vancouver
Hird M, Russell JJ, Corrigan LL, Boros I, Nordeman P, Antoni G, et al. Automated radiosynthesis of [ 18 F]CETO, a PET radiotracer for imaging adrenal glands, on Synthra RNplus. Journal of Labelled Compounds and Radiopharmaceuticals. 2024. doi:10.1002/jlcr.4078
BibTeX
@article{Hird2024,
author = {Hird, Matthew and Russell, Joseph J and Corrigan, Lei Li and Boros, Istvan and Nordeman, Patrik and Antoni, Gunnar and Gurnell, Mark and Aigbirhio, Franklin I},
title = {Automated radiosynthesis of [ 18 F]CETO, a PET radiotracer for imaging adrenal glands, on Synthra RNplus},
journal = {Journal of Labelled Compounds and Radiopharmaceuticals},
year = {2024},
doi = {10.1002/jlcr.4078}
}
EUVIMED